Results 41 to 50 of about 53,199 (230)
Advanced Science, EarlyView.Model illustrating the proposed mechanism by which chemotherapy‐induced downregulation of OGT disrupts SNAP29 O‐GlcNAcylation, promoting STX17‐SNAP29‐VAMP8 SNARE complex assembly and protective autophagy, leading to chemoresistance, which in turn establishes a feedforward loop to perpetuate drug tolerance.
Liang Tang +9 more
wiley +1 more source
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells
, 2008 The proteasome inhibitor bortezomib (PS-341/Velcade) is used for the treatment of relapsed and refractory multiple myeloma and mantle-cell lymphoma. We recently reported its therapeutic potential against natural killer (NK)-cell neoplasms.
Kwong, YL +7 more
core +1 more source
Advanced Science, EarlyView.Pasta is a transcriptomic aging clock built on an age‐shift learning framework and trained on 17 000 samples across 21 datasets. It accurately predicts relative biological age across tissues, platforms, and species, captures stemness‐to‐senescence transitions, and identifies age‐modulatory perturbations.
Jérôme Salignon +6 more
wiley +1 more source
Mediators of Inflammation, 2015 Bortezomib is a proteasome inhibitor used for hematologic cancer treatment. Since it can suppress NF-κB activation, which is critical for the inflammatory process, bortezomib has been found to possess anti-inflammatory activity.
Sheng-Min Hsu +5 more
doaj +1 more source
IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis
Advanced Science, EarlyView.The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui +12 more
wiley +1 more source
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
PLoS ONE, 2010 The proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma (MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of ...
Feng Ge +9 more
doaj +1 more source
Advanced Science, EarlyView.Targeted protein degradation is often limited by the scarcity of usable E3 ligases. Herein, we report the first small‐molecule GPX4 degraders that incorporate either electrophilic warheads or a minimal azide group as an E3 recruitment ligand. The azide‐based degrader DK‐5070 effectively drives potent GPX4 degradation; mechanistic studies reveal that ...
Zehong Lin +14 more
wiley +1 more source
Case Reports in Cardiology, 2016 Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Traditionally, bortezomib was thought to have little cardiovascular toxicity; however, there is increasing evidence that bortezomib can lead to cardiac ...
Sachin Diwadkar +2 more
doaj +1 more source
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5
JCI Insight, 2022 The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment.
Yan Yang +16 more
doaj +1 more source
Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
, 2013 Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma.
Utkarsh Painuly, Shaji Kumar
core +1 more source